Whitehawk Therapeutics (WHWK) Change in Accured Expenses (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Change in Accured Expenses data on file, last reported at -$3.5 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 458.36% year-over-year to -$3.5 million in Q1 2026; TTM through Mar 2026 was -$4.7 million, a 129.65% decrease from a year earlier, with the FY2025 full-year figure at -$202000.0, up 97.93% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.5 million, down from -$1.2 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for WHWK reached as high as $5.0 million in Q3 2022 and fell as low as -$10.2 million in Q4 2024.
• Historically, Change in Accured Expenses has averaged -$683266.7 across 5 years, with a median of $975000.0 in 2025.
• Across the five-year window, Change in Accured Expenses slumped 797.47% in 2022 and surged 279.66% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.3 million in 2022, then jumped by 279.66% to $4.9 million in 2023, then sank by 305.52% to -$10.2 million in 2024, then surged by 88.42% to -$1.2 million in 2025, then plunged by 196.86% to -$3.5 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$3.5 million in Q1 2026, -$1.2 million in Q2 2025, and $975000.0 in Q1 2025.